How long does it take for metformin to start working

Pro Research Analysisby

Searched over 200M research papers

Analyzed relevant papers

How Long Does It Take for Metformin to Start Working?

Metformin is a widely prescribed medication for managing type 2 diabetes (T2D). Understanding the timeline for its effectiveness is crucial for patients and healthcare providers. This article synthesizes findings from recent research to provide a clear answer.

Initial Effects on Glucose Levels

Short-Term Impact on Fasting Plasma Glucose

Research indicates that metformin can start to lower fasting plasma glucose (FPG) levels within a relatively short period. In a 12-week study, subjects with T2D who were administered various doses of delayed-release metformin (Met DR) showed significant reductions in FPG levels compared to placebo . This suggests that metformin begins to exert its glucose-lowering effects within the first few weeks of treatment.

Gut Microbiome Alterations

Metformin's impact on the gut microbiome also plays a role in its therapeutic effects. A study involving treatment-naive individuals with T2D demonstrated that metformin significantly altered the gut microbiota within four months . These changes in the gut microbiome were associated with improved glucose tolerance, indicating that metformin's benefits might be mediated through gut-related mechanisms.

Long-Term Benefits

Sustained Glycemic Control

The same 12-week study mentioned earlier also found that the reductions in FPG levels were sustained over the entire study period . This indicates that while metformin starts working relatively quickly, its full benefits in terms of glycemic control continue to develop and stabilize over a longer period.

HbA1c Levels

Changes in HbA1c levels, a marker of long-term blood glucose control, were consistent with the reductions in FPG levels observed over the 12-week period . This further supports the notion that metformin's glucose-lowering effects are both immediate and sustained.

Conclusion

In summary, metformin begins to lower blood glucose levels within the first few weeks of treatment, with significant and sustained effects observed over a 12-week period. Additionally, alterations in the gut microbiome contribute to its therapeutic effects, which become evident within four months. Therefore, patients can expect to see initial improvements in glucose levels relatively quickly, with continued benefits over the long term.

Sources and full results

Most relevant research papers on this topic

Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug

Metformin alters the gut microbiome in individuals with treatment-naive type 2 diabetes, contributing to its therapeutic effects and improving glucose tolerance.

RCTVery Rigorous JournalHighly Cited

2017·

1226citations

·Hao Wu et al.

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies

Metformin's primary glucose-lowering effect is predominantly mediated through the gut, not the circulation, with gut-restricted Met DR providing lower plasma exposure and better glycemic control in type 2 diabetes patients.

RCTVery Rigorous JournalHighly Cited

2015·

281citations

·J. Buse et al.

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

Metformin treatment in women with PCOS reduced hyperinsulinemia and hyperandrogenemia, leading to sustained improvements in menstrual abnormalities and resumption of ovulation.

RCTHighly Cited

2000·

769citations

·P. Moghetti et al.

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks

Saxagliptin + metformin initial combination therapy effectively and safely improves glycemic control in treatment-nave type 2 diabetes patients compared to saxagliptin or metformin alone for up to 76 weeks.

Non-RCTRigorous JournalHighly Cited

2011·

101citations

·A. Pfützner et al.

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

Dapagliflozin added to metformin for 102 weeks enabled sustained reductions in HbA1c levels and fasting plasma glucose levels in type 2 diabetes patients inadequately controlled with metformin.

RCTLarge Human TrialRigorous JournalHighly Cited

2013·

295citations

·C. Bailey et al.

Metformin extended‐release versus immediate‐release: An international, randomized, double‐blind, head‐to‐head trial in pharmacotherapy‐naïve patients with type 2 diabetes

Metformin extended-release (XR) is as effective and safe as immediate-release (IR) metformin for treating type 2 diabetes, with the advantage of once-daily dosing.

RCTLarge Human TrialRigorous Journal

2017·

33citations

·N. Aggarwal et al.

Metformin Discontinuation prior to FDG PET/CT: A Randomized Controlled Study to Compare 24- and 48-hour Bowel Activity.

Metformin discontinuation for 48 hours prior to PET/CT is associated with lower accumulation of fluorodeoxyglucose in the bowel compared to no discontinuation or 24-hour discontinuation.

RCTRigorous Journal

2018·

33citations

·R. Hamidizadeh et al.

Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes

Metformin delayed-release (Metformin DR) effectively reduces HbA1c and FPG levels in type 2 diabetes patients with minimal systemic exposure, compared to immediate-release Metformin.

RCTLarge Human TrialRigorous Journal

2018·

30citations

·R. Henry et al.

Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study.

Metformin significantly reduces body weight and improves metabolic abnormalities in clozapine-treated patients with schizophrenia, but these beneficial effects disappear after discontinuing the medication.

RCTHighly Cited

2013·

72citations

·Chun-Hsin Chen et al.

Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up.

Metformin extended release caused a small but significant decrease in BMI in obese adolescents when added to a lifestyle intervention program.

RCTHighly Cited

2010·

131citations

·Darrell M. Wilson et al.

Try another search

non cancerous skin growths pictures

difference between simvastatin and atorvastatin

metronidazole side effects

lactic acidosis from metformin

diabetes potential complications

escitalopram warnings